Trial Information

Summary: Combined Atherogenic Dyslipidemia

Phase 3 randomized, double blind study to evaluate the safety and efficacy of a triple therapy of a once daily study drug combined with 2 already marketed drugs. This study will last 16 weeks and patients will be compensated for their time and travel upon completion of study.

Patient Inclusion Criteria:

• Male or female 18 or older
• Fasting lipid results before baseline visit of TG level >150 and <400, HDL-C <40 for males and <50 for females and an LDL-C of >130
• Must have life expectancy greater than 6 months at the pre-screening visit

Patient Exclusion Criteria:

• Type I Diabetes or uncontrolled type II Diabetes
• Hepatitis B or C or hepatic cirrhosis
• Significant renal or neurological disorder
• Any unstable cardiovascular disease
• Malignancy within 5 years (except non-malignant skin cancer)
• Ketoacidosis

If you would like to learn more about participating in this study, please send an e-mail message using the form below.